Podcasts about Griffith

The interracial marriage debate is back. What is going on?! What does this tell us about our cultural moment? What does the Bible actually say about it? Sean and Neil Shenvi break down a recent debate between Ruslan and GodLogic (pro) and Webbon, Griffith, and Todd (against). Let us know what you think about the debate and if THIS kind of video is helpful on this channel. READ: Post Woke, by Neil Shenvi & Pat Sawyer (https://amzn.to/49Y2gSt) *Get a MASTERS IN APOLOGETICS or SCIENCE AND RELIGION at BIOLA (https://bit.ly/3LdNqKf) *USE Discount Code [smdcertdisc] for 25% off the BIOLA APOLOGETICS CERTIFICATE program (https://bit.ly/3AzfPFM) *See our fully online UNDERGRAD DEGREE in Bible, Theology, and Apologetics: (https://bit.ly/448STKK) FOLLOW ME ON SOCIAL MEDIA: Twitter: https://x.com/Sean_McDowell TikTok: https://www.tiktok.com/@sean_mcdowell?lang=en Instagram: https://www.instagram.com/seanmcdowell/ Website: https://seanmcdowell.org Discover more Christian podcasts at lifeaudio.com and inquire about advertising opportunities at lifeaudio.com/contact-us.

Today, on Karl and Crew, we discussed the power of prayer and how coming into prayer is a way to have intimacy with the Lord. Then we turned to the phone lines and asked, “Why do you believe in the power of prayer?” Then we had Jim Daly join us to share his story and how God has used it to stir his passion for helping restore biblical family structures. Jim is the President and Chief Executive Officer of Focus on the Family, which airs weekdays at 7:30 pm CT on Moody Radio. He is also the main host of the daily broadcast Focus on the Family and the host of The Refocus Podcast. He has also authored several books, including “The Good Dad”. Then Trent and Andrea Griffin joined us to discuss the impact of FamilyLife’s Weekend to Remember, a marriage getaway with the goal of oneness. Trent and Andrea are currently leading the effort to plant New City Church in St. Augustine, FL, a new church targeting one of the fastest-growing counties in the country. Andrea is also mentoring women in partnership with Parakaleo and the Church Hub. You can hear the highlights of today's program on the Karl and Crew Showcast. If you're looking to hear a particular segment from the show, look at the following time stamps: Trent and Andrea Griffith Interview [09:48] Listener Calls [16:55] Jim Daly Interview [37:38] Karl and Crew airs live weekday mornings from 5-9 a.m. Central Time. Click this link for ways to listen in your area! https://www.moodyradio.org/ways-to-listen/Donate to Moody Radio: http://moodyradio.org/donateto/morningshowSee omnystudio.com/listener for privacy information.

Today, on Karl and Crew, we discussed the power of prayer and how coming into prayer is a way to have intimacy with the Lord. Then we turned to the phone lines and asked, “Why do you believe in the power of prayer?” Then we had Jim Daly join us to share his story and how God has used it to stir his passion for helping restore biblical family structures. Jim is the President and Chief Executive Officer of Focus on the Family, which airs weekdays at 7:30 pm CT on Moody Radio. He is also the main host of the daily broadcast Focus on the Family and the host of The Refocus Podcast. He has also authored several books, including “The Good Dad”. Then Trent and Andrea Griffin joined us to discuss the impact of FamilyLife’s Weekend to Remember, a marriage getaway with the goal of oneness. Trent and Andrea are currently leading the effort to plant New City Church in St. Augustine, FL, a new church targeting one of the fastest-growing counties in the country. Andrea is also mentoring women in partnership with Parakaleo and the Church Hub. You can hear the highlights of today's program on the Karl and Crew Showcast. If you're looking to hear a particular segment from the show, look at the following time stamps: Trent and Andrea Griffith Interview [09:48] Listener Calls [16:55] Jim Daly Interview [37:38] Karl and Crew airs live weekday mornings from 5-9 a.m. Central Time. Click this link for ways to listen in your area! https://www.moodyradio.org/ways-to-listen/Donate to Moody Radio: http://moodyradio.org/donateto/morningshowSee omnystudio.com/listener for privacy information.

Send us a text"Key Questions" | Rev. Dr. Guy D. Griffith | preaching | 01.18.26

Host: Allan NewsomeRunning time: 0:53:27 Over the last 10 years, I have been fortunate to become friends with Dixie Griffith. Dixie is the daughter of Andy Griffith and back in 2015 she came to her first Mayberry event. Since that time she has attended many events, Mayberry cruises and all in all enjoyed experiencing the […]

The Hiding Man and Other Legends of LA's Griffith ParkBecome a supporter of this podcast: https://www.spreaker.com/podcast/missing-persons-mysteries--5624803/support.

SJG: https://chroniclesmagazine.org/view/woke-will-never-go-broke/ J: https://findmyfrens.net/jburden/ Buy me a coffee: https://www.buymeacoffee.com/j.burden Substack: https://substack.com/@jburden Patreon: https://patreon.com/Jburden GUMROAD: https://radiofreechicago.gumroad.com/l/ucduc Axios: https://axios-remote-fitness-coaching.kit.com/affiliate ETH: 0xB06aF86d23B9304818729abfe02c07513e68Cb70 BTC: 33xLknSCeXFkpFsXRRMqYjGu43x14X1iEt

Michael Diaz-Griffith's background is in the world of antiques—he served as executive director of the Sir John Soane's Museum Foundation, has held various positions at the Winter Show, and authored a book on the rise of young collectors, The New Antiquarians. He is now the CEO of the Design Leadership Network, one of the industry's key professional organizations, dedicated to connecting designers, architects, and business leaders through education and events.On this episode of the podcast, Diaz-Griffith speaks with host Dennis Scully about the challenges and opportunities ahead in 2026, class issues in design, and why his goal is to show up more and more as himself.This episode is sponsored by ErnestaLINKSMichael Diaz-GriffithThe Design Leadership NetworkDennis ScullyBusiness of Home

On today's program: Casey Harper, Managing Editor for Broadcast at The Washington Stand and Host of the "Outstanding" podcast, provides an update on protests in Minnesota and other cities, and President Trump's comments on Iran, Venezuela, and Cuba.

Dai nostri archivi, la storia di Fabiola Valtolina: arrivata in Australia senza sapere una parola d'inglese, ha scoperto il "country" a Griffith prima di tornare a Sydney, dove sta iniziando una carriera nella stand-up comedy.

We sit with Visit Bentonville CEO Kalene Griffith to trace how a destination management approach turns visitor spending into daily life upgrades: better parks, a busier library, a thriving community center, and a steady calendar of film, cycling, art, and sports events that fill rooms and keep families out playing after dark. From Phillips Park and Lawrence Plaza to Memorial Park upgrades, Kaylene lays out how small, targeted investments add up to a livable, lovable city. Looking ahead to 2026, we explore a bold slate of priorities: a unified wellness story that connects spas, trails, and healthy dining; added cycling and sporting events, and more. The new destination master plan pairs resident feedback with a growth blueprint designed to protect what locals love while welcoming the world. If you care about sustainable growth, hospitality careers, and how tourism can raise quality of life, this is your playbook.Learn more at visitbentonville.comA New American Town is here to help you plan your trip to Bentonville, Arkansas. From guides, events, and restaurant highlights. Find all this and more at visitbentonville.com and subscribe to our newsletter. Follow us on Facebook, Instagram, TikTok, X, and LinkedIn. You can listen to this podcast on Apple Podcasts, Overcast, Spotify, CastBox, Podcast Casts, Google Podcasts, iHeartRadio, and Podcast Addict.

This Week on ART ON THE AIR features the lead actor in the film “Christmas in Chicago,” Julian Griffith, also discussing his sports training academy Juiced Up Athletics. Next GRAMMY®-nominated violinist Anna Marie Williams, a founding member of the critically acclaimed Neave Trio, discussing her career and the release of their album, La Mer – French Works for Piano Trio.Our spotlight is on the LaPorte County Symphony's February 7th concert “The Roaring 20s: A Celebration of America's Jazz Age,” at La Porte High School Performing Arts Center

For decades, snack companies believed Americans wanted everything sweeter.More sugar. More chocolate. More indulgence.But what if that assumption was wrong?In this episode, a mother-daughter team set out to make a sleeker version of a chocolate almond— and nearly lose everything in the process.Val Griffith was a longtime TV producer in Seattle. Her daughter Breezy was bouncing between failing business ideas in Miami and New York. When a family tragedy brought Breezy back home, the two began talking about food, snacking, and why chocolate-covered almonds were always so… overdone.Their insight was deceptively simple: what if you used less sugar, not fake sugar — and a thin coating of chocolate instead of a fat one? Turning that idea into SkinnyDipped meant years of failed experiments, dipping almonds by hand, manufacturing out of a converted chicken coop, and demoing almonds one by one. When they finally got a breakthrough order from Target, they faced a near-disaster: 40,000 pounds of rancid almonds. What followed was a frantic race to save the deal — and later, a far more dangerous question: is this business ever going to make it?WHAT YOU'LL LEARN: How failing at micro-businesses quietly builds founder skillWhy manufacturing is often the biggest obstacle in food startupsThe nail-biting risk of saying yes to Target too earlyHow growth can mask deeply broken economicsWhat it takes to fix a business when funding disappearsTIMESTAMPS: 00:07:25 - How Breezy's early forays into the food business failed — and why they mattered.00:11:00 - How a family loss brought Breezy and her mom together — and changed the direction of their lives 00:21:07 - Reinventing a stale bulk-bin snack: The road-trip conversations that sparked a new recipe: 00:31:20 - The Home Depot paint sprayer experiment: A brilliant idea that failed spectacularly.00:38:56 - SkinnyDipped's first “facility:” one oven, no heat, no hot water 00:49:28 - How a chance meeting in a bar changed the company's trajectory00:55:41 - Target takes the plunge and SkinnyDipped nearly drowns: how a chain-wide launch almost breaks the business01:7:47 - Growth without profit: How the founders recover after hitting rock bottom01:21:44 - The mother-daughter equation: wisdom + jet fuel01:26:13 - Small Business Spotlight —-----------------------Hey—want to be a guest on HIBT?If you're building a business, why not get advice from some of the greatest entrepreneurs on Earth?Every Thursday on the HIBT Advice Line, a previous HIBT guest helps new entrepreneurs work through the challenges they're facing right now. Advice that's smart, actionable, and absolutely free.Just call 1-800-433-1298, leave a message, and you may soon get guidance from someone who started where you did, and went on to build something massive.So—give us a call.We can't wait to hear what you're working on.—-----------This episode was produced by Kerry Thompson with music composed by Ramtin Arablouei. It was edited by Neva Grant with research help from Chris Maccini. Our engineers were Robert Rodriguez and Kwesi Lee.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Legends of Los Angeles: Griffith ParkBecome a supporter of this podcast: https://www.spreaker.com/podcast/missing-persons-mysteries--5624803/support.

Rebekah Griffith joins the podcast to talk about what it means to be a newly minted AAOMPT Fellow working in one of the most unlikely settings — the Emergency Department.She shares why OMPT-level manual therapy skills are not only relevant in the ED, but essential for rapid assessment, safe decision-making, and efficient patient care. Rebekah explains how fellowship training sharpened her clinical reasoning, helped her manage acute MSK presentations, and expanded her impact within emergency medicine teams.In this episode: • The PT's role in the ED • How manual therapy speeds clarity and improves outcomes • Examples of OMPT reasoning in acute, high-stakes scenarios • Why fellowship training matters outside outpatient ortho • Reducing unnecessary imaging, opioids, and admissions • Rebekah's journey through AAOMPT Fellowship and into ED practiceWhether you're a clinician, student, or educator, Rebekah's perspective will reshape how you think about where — and how — manual therapy skills should be used.

PESTO Trial Results: What Stroke Survivors Need to Know About Perispinal Etanercept If you've spent any time in stroke recovery communities, you've probably seen the same pattern: a treatment gets talked about with real intensity, people share personal stories that pull you in, and suddenly you're left trying to sort hope from hype from “maybe.” When the decision also involves significant cost, that uncertainty can feel even heavier. That's exactly why I recorded this episode: to help stroke survivors and their families understand the PESTO trial results in plain language without drama, without attacks, and without jumping to conclusions. In this interview, Professor Vincent Thijs explains what the PESTO trial set out to test, why it was designed the way it was, and what the results can (and can't) tell us about perispinal etanercept in stroke recovery. The real problem: not “hope vs skepticism”… it's confusion If you're a stroke survivor, you're already doing something heroic: you're living inside a recovery journey that demands patience, grit, and constant adjustment. The challenge isn't that you “don't want to believe” in something. The challenge is that it's genuinely hard to make an informed decision when: People report different outcomes Online conversations become polarised fast Scientific studies use unfamiliar language The same treatment can be described in completely different ways depending on who you're listening to My goal here isn't to tell you what to do. It's to help you think clearly, ask better questions, and understand what the best available evidence from this trial actually tested. What the PESTO trial was trying to investigate (in simple terms) Professor Thijs explains that the PESTO trial was designed in response to strong community interest. Stroke survivors wanted to know whether the way perispinal etanercept is currently administered in some settings could be demonstrated to work under the standards used for medicines to become widely accepted as part of routine care. So the researchers designed a randomized, placebo-controlled clinical trial. In this type of study: A computer assigns participants to either the treatment or a placebo Participants and clinicians are kept “blinded” (they don't know who got what) Outcomes are measured in a consistent way at set time points In the PESTO trial, the focus was on stroke survivors with moderate to severe disability and reduced quality of life. The primary question was straightforward: Does quality of life improve after one or two injections compared with placebo, over the measured timeframe? Why this study looked at quality of life (not one symptom) One key detail Professor Thijs highlights is the design choice: the trial didn't only target one issue, like pain or walking. It aimed to be more “pragmatic,” reflecting how treatment is used in real-world settings where people seek help for different post-stroke challenges (mobility, fatigue, speech, cognition, pain, and more). That means the main outcome wasn't “Did walking speed improve?” or “Did pain reduce?” It was broader: Quality of life at 28 days And again after the second injection timeframe (56 days total) This matters because your results can look different depending on what you measure. A trial targeting one symptom might see a signal that a broad quality-of-life measure doesn't detect (and vice versa). What the PESTO trial results found In Professor Thijs' words, the trial did not show a difference in quality of life between the treatment and placebo groups at the measured time points: No clear quality-of-life improvement at 28 days No clear improvement after two injections at 56 days That's the central outcome. But there's another finding that grabbed my attention—and it's one many listeners will find surprising. Quote block (mid-article): “We saw that 58% of the people also had that improvement [with placebo] and 53% had it with etanercept… our initial guess was very wrong.” — Professor Vincent Thijs The “placebo signal” and why it matters A strong placebo response doesn't mean “it was all in their heads.” It means that in a blinded clinical trial, people can improve for multiple reasons that aren't specific to the drug itself, such as: Expectation and hope Natural fluctuations in symptoms The impact of being monitored and supported Regression to the mean (symptoms often move toward average over time) The structure and attention that come with trial participation Professor Thijs describes how, during the blinded phase, participants reported improvements in a variety of areas (like sensation, vision, speech). The crucial point is: the team didn't know who had a placebo or an active treatment at the time, which is exactly why blinding exists. For you, the listener, this is a reminder of something empowering: Personal stories can be real and meaningful—and still not answer the question of efficacy on their own. “Am I a candidate?” The trial's honest answer: we don't know how to predict it (yet) One of the most important parts of this conversation is the desire to identify who might benefit most. Professor Thijs explains that the team looked at subgroups (for example: age, sex, severity, diabetes, time since stroke). In this trial, they didn't find a clear subgroup where the treatment stood out as reliably beneficial compared with placebo. He also adds an important caveat: subgroup analysis is difficult, especially in trials that aren't extremely large. So the absence of a clear “responder profile” here doesn't automatically prove none exists—it means this trial didn't reveal one. What this episode is (and isn't) saying Let's keep this grounded and fair. This interview is not about attacking any person, provider, or clinic. It's not about shaming stroke survivors who tried something. It's not even about telling you that you should or shouldn't pursue a treatment. It is about this: Understanding what the PESTO trial tested Understanding what the results showed within their timeframe Knowing the limits of what the trial can conclude Using evidence to reduce confusion before making big decisions A simple “clarity plan” before you decide anything big If you're considering any high-stakes treatment decision, here's a neutral, practical way to move forward: 1) Ask: “What outcome matters most for me?” Is it pain? walking? fatigue? speech? cognition? daily function? quality of life? A treatment might be studied for one outcome and discussed online for another. 2) Ask: “What does the best evidence say—specifically?” Not “Does it work?” in general, but: In what population? Using what method? At what dose? Over what timeframe? Compared with what? 3) Ask: “What are my options and trade-offs?” Talk with a qualified healthcare professional who understands your medical history, risk factors, and rehab plan. Ask about: Potential risks and side effects Opportunity cost (what else could you do with the same time, money, and energy?) Evidence-based rehab and supports that match your goals Listen to the full interview If you want the clearest explanation of the PESTO trial results—from the lead researcher himself—listen to the full episode with Professor Vincent Thijs. And if you'd like to support the podcast (and help keep these conversations going for stroke survivors who need hope and clarity): Bill's book: recoveryafterstroke.com/book Patreon: patreon.com/recoveryafterstroke Medical disclaimer This blog is for informational purposes only and does not constitute medical advice. Please consult your doctor before making any changes to your health or recovery plan. PESTO Trial Results (Etanercept After Stroke) | Interview with Professor Vincent Thijs Confused about perispinal etanercept after stroke? Prof Vincent Thijs explains the PESTO trial results clearly, calmly, and evidence-first. More About Perispinal Etanercept: Etanercept Stroke Recovery: Wesley Ray's Relentless Comeback Dwayne Semple's Remarkable Stroke Journey and Perispinal Etanercept Etanercept for Stroke Recovery – Andrew Stopps Support The Recovery After Stroke Podcast on Patreon Highlights: 00:00 Introduction and Overview of the PESTO Trial 04:19 Design and Objectives of the PESTO Trial 11:23 Recruitment and Methodology of the Trial 18:31  PESTO Trial Results and Findings 24:28 Implications and Future Directions for Research 32:15 Conclusions and Final Thoughts Transcript: Introduction: PESTO Trial Results Bill Gasiamis (00:00) Hello and welcome back to Recovery After Stroke. Before we get started, a quick thank you to my Patreon supporters. Your support helps cover the hosting costs after more than 10 years of me doing this show solo. And it helps me keep creating episodes for stroke survivors who need hope and practical guidance. And thank you as well to everyone who comments on YouTube, leaves reviews on Spotify and Apple podcasts. buys the book and even to those of you who don’t skip the ads. Every bit of that supports keep this podcast going. Now today’s episode is about the PESTO trial results and I’m interviewing Professor Vincent Theis. If you’ve ever felt confused by the conversation online about perisponal antenna sept, some people sharing positive experiences while others are feeling disappointed and plenty of strong opinions in between, this episode is designed to bring clarity. We talk about what the PESTO trial set out to test, how the study was designed, what it found within the measured timeframes and what the results can and can’t tell us. Just a quick note, this conversation is educational and not medical advice. Always speak with a qualified health professional about your situation. All right, let’s get into it. Professor Vincent Dase, welcome to the podcast. Vincent Thijs (01:24) Thank you for having me, Bill. Bill Gasiamis (01:26) I’m really looking forward to this conversation. Atenosept is one of the most hotly discussed topics in stroke recovery. And there’s a lot of misconceptions about whether or not it is or is not efficacious. And while there’s a lot of anecdotal evidence where some people have had positive outcomes from injections, there’s also a lot of people’s feedback, which is very negative about their experience with the Etanercept injections and the lack of results. So today, the reason I reached out is because I wanted to get to the bottom of the findings of the PESTO trial. And I’m hoping that you can shed some light on that. The first question basically is, can you start by explaining in simple terms what it was that the PESTO trial set out to investigate? Vincent Thijs (02:22) All right. The PESTO trial was in response to community members, stroke survivors, wanting to find out whether the current practice of administering Etanercept has done in the U.S. in private practice. In Denmark, I hear there are some sites that provide this treatment. Whether the treatment and genders can be actually proven according to the standards that we use in the pharmaceutical industry to get it to become accepted as a standard of care treatment. For that, you need to do what we call a randomized controlled clinical trial, preferably two that show evidence that treatment does what it’s set out to do. And that’s why with this background and the community pressuring the minister several years ago, Mr. Hunt at the time, to fund a trial that would help answer that question. Design and Objectives of the PESTO Trial There was a call was set out to do this trial and several groups in Australia applied and then an independent committee decided to award the trial to the PESTO study group. And then we tried to design this trial to give an answer. So it’s mostly about people that have moderate to severe disability after their stroke that have reduced quality of life. And We wanted to know, does their quality of life improve when Etanercept is administered? And we wanted to test whether one or two injections were needed. Because that’s what we heard from stroke survivors that from Australia and internationally that went over to the US. Well, this is how it’s done. You get one or two injections and there was a paper that had shown big effects with one injection. So that was the primary endpoint, but then we also looked at whether two injections could help. And when you design a trial, you have to make a decision, will we focus on people with. pain after stroke, or will we look at people who have mobility issues or speech issues or cognitive issues? And we saw that current clinical practice actually was people with various impairments after stroke were accepted and received the treatment. And what would have been the advantage of doing say only mobility or only pain? Well, you can then look at the outcome of pain or mobility, does it improve? Or is your cognition improved? But because we wanted to be pragmatic and we know that recruitment in clinical trials needs to reflect how is current practice. So we thought let’s put in all the people with moderate to severe disability, whatever their impairment after stroke and reduce quality of life. And then we looked at quality of life as an outcome rather than an individual impairment. And so what we did then was to use the randomized technique and where it’s left up to the computer to decide what treatment a person will receive, the active Etanercept or a similar looking placebo, and then look at 28 days and we had to make a decision what makes sense 28 days, what is practical. to see whether that injection then had improved quality of life. And then we did another injection again with a placebo or the active drug. And then after 28 days again, we looked again whether that had made a difference. So we have people that had received two times the placebo, one time the placebo, and one active injection. And then we have people that had received two active injections. And then we were able to compare those and see whether they had made bigger improvements if you receive two injections versus one or zero. Unfortunately, we couldn’t show a difference in quality of life at 28 days. And we also couldn’t show an improvement at 56 days after people had two injections. But that was in a nutshell how we designed and the background of the study. Bill Gasiamis (07:25) So the main difference then between the Griffith University study and your particular study was that they did go after a specific improvement in one area, I believe. it in? Okay. So although those guys went after pain, you guys went after just a general improvement in quality of life after the injection and your stroke survivors. Vincent Thijs (07:39) Mostly, think. Bill Gasiamis (07:54) would have been as far as 15 years post stroke. Is that right? Vincent Thijs (07:59) Yes, correct. We wanted to have people early after stroke between one and five years, and then also between people five to 15 years after stroke. That was also for practical reasons. Once you start trial, you see how good recruitment is, how many people want to participate in the study. And we saw that if we went to up to five years. Recruitment was relatively slow. So we added this additional group of people later on after their stroke. that because many people, I’m five years, I’m six years after stroke. Why can’t I get the treatment? And you know, so we also wanted to expand the pool. And that’s also what happens in clinical practice. Current clinical practice, I don’t think the sites and the US and they would refuse the patient six years or so. We just wanted to reflect the people that we see on the website going for this treatment. Bill Gasiamis (09:01) Yeah, yeah. And then the difference between the Griffith trial and your trial as well was the actual dosage of Etanercept the amount that was in the injection. I do believe that your trial was a 25 milligram injection. And I believe that the Griffith University trial was 25 milligram. injection to 50 milligram injection. Vincent Thijs (09:34) Yeah, we just based on what people told us they received when they went to the clinic, also the other sites and then also 35 milligram was chosen because that’s in the patent for the street. Bill Gasiamis (09:49) Okay, I see. So you’re trying to as much as possible mimic what was happening out there in in the private practice Vincent Thijs (10:00) We wanted to answer the question, is current clinical practice, is that beneficial? And that’s what sort of what the call was to do a clinical trial in current clinical practice. You can, you have to make decisions, right? And I think this was the most relevant for a stroke survivor. Bill Gasiamis (10:17) Now that’s really interesting that stroke survivors were able to twist the arm of a minister to get the funding to begin that process of the trial. How long ago did this actually start? Vincent Thijs (10:28) I think it was 2016, 2017 or so. So it takes a while to get the minister and then I think that the trial started in 2019. took a while to complete as well. Bill Gasiamis (10:43) Right understood. Okay So then you recruit people they come along and they go through the trial through the particular trial How does that work on the day do they turn up are they admitted? We’ll be back with more of professor face explanation in just a moment But I want to pause here because if you’ve ever felt stuck between hope and uncertainty, you’re not alone When you’re recovering from stroke, you’re constantly making decisions and some decisions feel high stakes, especially when confronting information that’s conflicting. Recruitment and Methodology of the Trial In the second half of this conversation, we get into the parts that really help you think clearly. What the trial results do and don’t mean, and why placebo responses matter in blinded research, and how to frame smarter questions before you commit time, money, or energy to any path. If you want to support the podcast and keep these episodes coming, You can grab my book at recoveryafterstroke.com/book or join the Patreon at patreon.com/recoveryafterstroke All right, back to the episode. Vincent Thijs (11:51) All right, so we recruited from a variety of sources. So we had kept a log of people that were interested in this. We had a Facebook post in New Zealand, for instance, where we recruited as well. We had people from the Stroke Clinical Registry that were approached. We had a website and people could register their interest if they were doing a search online to participate in clinical trial. So the variety of sources and then we have to determine eligibility that was mostly done either via an in-person visit or remotely via telehealth. We tried to get their medical information, what type of stroke they had. And then we also questioned whether they had this modified rank in scale, the disability they had, the impairments they had from their stroke. so then people came. they were considered eligible, then we scheduled a visit and they would typically come in no overnight stay needed. It was a day procedure that was done. People were then receiving another questionnaire on the day itself to measure their quality of life and other measures like their fatigue levels and how much help they required, etc. And then we proceeded with the injection, which was done. We had bought a special bed that was able to do the, the, the tilting that was required. So we set the people up, injected and then tilted the table. so, we received the drug. It was prepared independently by the pharmacist. So the pharmacist, they took the drug off the shelf or the made the placebo. and they made sure it looked exactly alike. So then somebody from the trial team picked it up from the pharmacist. The pharmacist didn’t tell, of course, what it was. And then the administration happened. So the doctor who administered and the participant did not know what they received. So after the procedure, they were left like this for four minutes. And then after four minutes, people could sit up again. And we waited about half an hour. then we asked them how they were doing, whether there were any adverse reactions, ⁓ and ⁓ then after that half an hour of observation people could go back to their habitual situation. ⁓ it’s a very simple ⁓ procedure to do. Bill Gasiamis (14:35) I believe there was a was there 126 participants Vincent Thijs (14:40) Yes, 126 people participated. had anticipated a little bit more people to participate. So we had hoped 168, but recruitment fell flat after a while and we were not able to find more people to recruit. So we made a decision and then, you know, these clinical trials, they have some funding ⁓ and they require the treatment team to be paid, et cetera, and that ran out. So we had to stop at a certain time. Bill Gasiamis (15:13) Was the study stopped early because of a decrease in the amount of funding or was there an issue with the funding at some point? Vincent Thijs (15:23) Funding ran out. You hire people for a certain amount of years and then you have fewer patients than you anticipate. So you have to stop. Bill Gasiamis (15:32) huh, okay. So would that affect the outcome of the trial? Would you say the lack of funding or the lack of the ability to take the trial further? Vincent Thijs (15:42) Yeah, well, what we had when you do the trial, when you plan the trial, you say, well, this is what we’re going to expect in terms of efficacy. You have to make a guess and say, well, that many people will have an improvement in quality of life if we give them the placebo and that many people will have an improvement in quality of life with the trial drug. And we had thought that about 11 % would improve with the placebo based on an earlier study. And then we had to make a guess because nobody had done this type of study on what Etanosap would provide. But reading the report that was published several years ago now, where 90 % of the people reported improvement in their impairments, we thought, well, Let’s not go for 90%, but a 30 % improvement. And so that was based on that we needed 168 people to participate in the trial. So that was what we call the pre-planned sample size estimation, which is a guess. When we stopped at 126 participants, actually we saw that the results were very different. There was not that 11 % actually in the placebo arm. saw that 58 % of the people also had that improvement and 53 % had it with ethanosab. So our initial guess was very wrong based on some statistical advanced statistical techniques we have. We have quite a lot of power to estimate whether there was a difference. So I think the trial can provide us an answer. It’s large enough to give us an answer about this particular question. Is current clinical practice in these people with this range after their stroke, does it improve? quality of life after a month or after two months. I’m not speaking about early improvement, I’m not speaking about six months down the line. We only can decide what we see in this study. Bill Gasiamis (18:05) So you have some limitations because you can’t have the funding to test one month, two months, six months, 12 months. You have the funding to basically meet the design of your study and then you can report on that. Now what’s really interesting is that the placebo had such a large result. PESTO Trial Results and Findings Vincent Thijs (18:34) What kind of things were people reporting that improved for the people who had the placebo injection?Look, this is, course, when we were in the blinded phase, when neither myself or my colleagues who did these scales, we were totally blinded. And that’s, remember vividly people saying, it didn’t do anything for me. But then there were also people said that they could see again. And so people that had improvement in sensation. Some people had improvement in their speech. there were, we, we observed these things, but we didn’t know whether they were active or placebo. And then surprisingly we had some people in whom we thought, they must have had active drug that turned out to have the placebo, but that’s years after, right? Because it takes a little bit of time to accumulate a sufficient number of patients. And we were only reporting and breaking the blind when the trial was finished. because otherwise you may be biased in all your analysis, et cetera. You don’t want to do that. So you wait until the end of the study to break the blind. And that’s very frustrating for the participants because there were many people that said, I must have had the placebo because it didn’t do anything for me. And there were other people that were, and some people like that, they said, I still want to go to the US. Bill Gasiamis (19:37) I see. Vincent Thijs (19:59) And please, can you tell me if I received a placebo? And I understand it was terribly frustrating for these participants. But we were very strict. No, we don’t want to break the blind. This is against the rules that you have to adhere to in a clinical trial. And so we didn’t do that. Of course, once the trial was finished, we were able to report the results back to the the participants. And then there were some people that were very surprised that they had received the active drug. I remember one person vividly who said, you have to tell me now because I’m going. And then I said, hold off, hold off. And then we told them you had twice the active drug. And so they decided not to go anymore. So you see how From a clinical trial perspective, it’s very important to remain very objective and not being able to see what people have received. From a humane level, of course, I understand it was very important to these people. Bill Gasiamis (21:02) Yeah, that’d be difficult. ⁓ And then I imagine that had the placebo not worked and then the tenisept did work, then there would have been people who would have said, well, I’ve received the placebo. It didn’t work for me. Other people received the tenisept. It did work for them. Why can’t I get the tenisept injection now? Vincent Thijs (21:26) Yeah, and we also had two people, people that had twice the placebo who noticed an improvement and have told me the improvement is still there. Bill Gasiamis (21:35) Wow. Vincent Thijs (21:36) So it. Bill Gasiamis (21:38) That’s amazing. Now was the. Vincent Thijs (21:40) And often that, and I must tell you, often those were relatively little things that seemed to improve both with the placebo and in the active group. And you see that there are changes in quality of life that people have reported, but it happens as well with the placebo. Bill Gasiamis (21:58) Wow. Was the intention of the study that was funded at the very beginning in 2016 by Minister Hunt, was it to determine whether or not this was going to be an effective treatment for people in stroke and therefore to roll it out somehow in the Australian medical system for stroke survivors? What was the thinking for Minister Hunt? Do you know? Vincent Thijs (22:24) Of course, I was not involved in that lobbying to the minister or anything, but it was to bring it on a pathway towards regulatory approval. We know that Etanercept is a relatively cheap drug that you can get ⁓ and is approved already for some indications, especially in people with rheumatoid arthritis, the condition of the joints, but it’s not approved for stroke. And to be officially approved and then potentially re- reimbursed on the PBS. You need to have some trials that have been done such as PESTO. We do different trial phases. One would be a phase two trial and a phase three trial. So phase one is typically in people just to assess the safety and some dosages usually in healthy people. And then a phase two is safety amongst stroke survivors. and preliminary efficacy. And that’s where PESTO was what we call a phase two B trial. And then a phase three trial would then be a trial in many more participants based usually on the results of a phase two B trial. And then usually when you have a phase three trial and it’s convincing and the authorities may approve such a trial. Bill Gasiamis (23:46) So in this case, the phase two B trial, this PESTO trial didn’t find that it’s efficacious. And as a result, there’s not going to be a further trial. Would that be accurate? Vincent Thijs (23:56) Well, based on the findings we have in this particular type of ⁓ way of administering in this particular group of people, I don’t think there’s enough evidence to argue for a phase three trial. It may be that you could say, well, we want to focus on pain because that was more promising. Well, you’ll need to do another trial in that condition. Implications and Future Directions for Research After stroke or maybe within a year after stroke. I mean, there are other possibilities, but at the moment, current clinical practice type trials, I don’t think there’s enough evidence to move forward with that. Bill Gasiamis (24:43) What would the numbers have had to look like for the trial to conclude that there was evidence of efficacy? Vincent Thijs (24:51) Well, I think based on what we have now, you would need to design a much, much bigger trial because there was only a 5 % difference between the placebo and the active group. And actually it was in favor of the placebo. So the placebo did a little bit better, not statistically significant. So it could just be by chance, but you would need probably thousands of people. Bill Gasiamis (25:15) I see. And I imagine there’s not a lot of excitement about funding something like that by the people who fund these trials. Vincent Thijs (25:25) Yes, typically the funders will look at how good is the evidence to pursue this. And if you were a pharmaceutical company on a pathway to development for a drug, you probably would say, well, it looks safe, but it didn’t do what it intended to do. So let’s stop the development of this drug for this indication. Bill Gasiamis (25:45) I say so. I think one of the challenges with the path of administering a TANACEP to stroke survivors is that there seems to be a missing step. And the step to me is determining whether or not somebody is a candidate for a TANACEP. perhaps if we knew more about the stroke survivor, what was actually happening in their particular brain, and we were able to determine some similarities between the people who have had a positive result and we developed a method, then that would make it a lot easier. to say, well, I’m a stroke survivor. I’d like to have a TANACYPT and then go through a process of determining whether or not I was a candidate rather than just guessing whether I’m a candidate or not and then having to pay money to find out whether in fact I was a candidate. Vincent Thijs (26:33) The trial provides a little bit of answers to that. ⁓ You want to identify a marker or a subgroup of people in whom the drug will work particularly well. And so you could look at, and we looked at different things like females versus males, if you’re younger versus older, if you have very severe disability or less severe disability, if you have diabetes, are you early after your stroke or later? That one to five versus six to 15 category. And we could not identify a group in whom the the drug worked particularly well. Now there’s a caveat when you do a clinical trial, it’s really hard to look at subgroups, especially if your trial is relatively small and the PESTO trial is relatively small. So you have to take this with a grain of salt, but it was nothing really promising. that we could identify. So probably you need other markers. If you believe in Etanercept as a drug, you would possibly need to look at what are the levels of TNF alpha, the drug, the molecule that actually is targeted. Unfortunately, there’s nothing like readily available to do that. Could it be that people with a… a stroke in a particular location that would work particularly more than in others, but we don’t have any real way at the moment to do that. Bill Gasiamis (28:08) Okay, so we’re assuming that the people who experience an improvement after they’ve had an attempt to shut that the markers of TNF alpha were lower or higher or Vincent Thijs (28:21) Well, the theory is that they have a lot higher TNF-alpha. Now, as you know, the premise is Etanercept works by reducing this molecule and we have good evidence that it reduces this molecule in the blood, but we don’t have good evidence that it reduces the levels in the brain. That’s where you want it to be. And one of the difficulties and many scientists that work on the Etanercept and ⁓ have said, look, it doesn’t cross the blood-brain barrier. It doesn’t. go against the natural defense that we have to protect the brain against substances that could potentially be harmful for the brain or that have a large size. And the Tandacep we know has a large size would not cross the blood-brain barrier. So it doesn’t reach the brain. And many people look at it with relative skepticism that it actually enters the brain. Bill Gasiamis (29:18) ⁓ And then with regards to rheumatoid arthritis, doesn’t need to cross the blood-brain barrier. It just somehow gets to this, position or the place where inflammation is occurring. TNF-alpha is active and it can easily mitigate the impact that TNF-alpha is causing. In the brain, the brain is protected by the blood-brain barrier and it cannot cross the blood-brain barrier under normal conditions and therefore it can’t get to where the TNF-alpha is. if there’s any TNF alpha, if inflammation is the issue and it cannot resolve it one way or another. So for some people perhaps it can’t resolve it. Now, I don’t understand about Etanercept a lot. I don’t understand exactly how the molecule works, et cetera. But if it was injected into a blood vessel, is that not something that can occur? And if it was, if it can occur, would that then cross the blood brain barrier? Vincent Thijs (30:15) That wouldn’t cause a blood brain barrier, no. You would have to do what we call a lumbar puncture or put a little ⁓ injection into the ventricles and then hope that it would enter the area that is stark where the TNF alpha is elevated. Those experiments have not been done. Bill Gasiamis (30:17) Either. Okay, so a lumbar puncture is probably riskier than… Vincent Thijs (30:44) Well, it’s uncomfortable. It’s uncomfortable and we do it to administer drugs if needed. Some people with brain cancer receive it. There are other trials ongoing in certain areas of stroke where it’s done. Bill Gasiamis (30:58) Then the difficulty is, and my job here is to report back to the community how they should proceed with Etanercept going forward. Now, I don’t expect you to answer that. However, your study probably gives enough information for people to be able to make an even more informed decision than they did before. Previously, what I think was happening is people, and it still happens every day. And I’ve interviewed a lot of stroke survivors who’ve had positive results with Etanercept. The challenge is getting interviews with stroke survivors who have had negative results with Etanercept. That is something I haven’t been able to do. So if somebody happens to be watching and listening to this and they have had the Etanercept shots and they didn’t get positive results, please reach out so that we can share a balanced story of what’s happening out there in the community. Would there be a reason for the community to perhaps begin again to lobby a government or a minister of a government to look at perisponinal tenosept and study it in a different way, like administration via a lumbar puncture. Conclusions and Final Thoughts Vincent Thijs (32:08) I think we need more, probably go back to the drawing table to see whether, because we’re just taking a step back. The idea is that there is inflammation after stroke and we know that there is inflammation after stroke. We don’t, we just don’t know how long it is. We don’t have a good marker. Is it present only for weeks or months after stroke or can it persist for years? The theory is that it persists for years, but if you look at the actual experiments that have been done, it’s really hard to study in humans because we don’t have good tests. But if you look in animals, it’s also hard to do long-term studies in animals, but nobody has really proven that conclusively that there is still after the stroke causes a scar, that process is still really active. Is TNF-alpha years after a stroke still present? Yes, it’s present because we use TNF as a transmitter in the brain or a chemical in the brain, but is it still worth reducing its activity? That’s probably, I think, a bigger question that science needs to answer is to understand that all inflammation piece and the time after stroke that it persists in my Bill Gasiamis (33:35) Yeah, because it could still be the fact that the person has had brain damage. The particular part of their brain that’s damaged has, for example, taken offline one of their limbs and there is no way to recover that once it’s gone. there is no, there may also be no inflammation ⁓ there. So somebody in that situation receiving Etanercept wouldn’t get a result even if it was able to cross the blood-brain barrier because the damage is done and that’s the challenge with the brain is once it’s damaged restoring the damaged part is not possible. Vincent Thijs (34:15) Yeah, look, after this experience with the PESTA trial, I think we need to work on other avenues and I’m not as hopeful with this based on the data that I have seen. Bill Gasiamis (34:28) Yeah Well, my final question then is, are you planning on exploring inflammation and recovery after stroke with any work that you’re doing in the future? Is there any more of this type of work being done? Vincent Thijs (34:46) we’ve just launched a new study, which is not a randomized trial, but it’s trying to get at this common symptom that people have after stroke, which is fatigue and cognitive changes. And one of my post-docs, Dr. Emily Ramech, she’s a physio by background. We just launched what we call the deep phenotyping study after stroke. And we are looking at young people that have had a stroke up to age 55 and we’re taking them into the scanner. We will do a PET scan that’s looking at inflammation. We’re taking their bloods and looking at markers of inflammation and see how that relates to fatigue after stroke. This is between the first month and the sixth month after stroke. That will give us a little bit of timeline of inflammation after stroke. It will give us some information about fatigue, which is very common, but I have no plans at the moment to look at ethanocephaly. Bill Gasiamis (35:53) Fair enough. I appreciate your time. Thank you so much. All right, well, that brings us back to the end of the episode with Professor Vincent Dease on the PESLO trial results. My hope is that this conversation gives you more clarity, especially if you’re felt caught between personal stories, strong opinions, and a lot of uncertainty. The goal here isn’t to tell you what to do. It’s to help you ask better questions and make decisions with your eyes open alongside a qualified healthcare professional who knows your situation. If this episode helped you, please do a couple of things. Subscribe on YouTube or follow the podcast on Spotify or Apple. Leave a review if you can. It really helps more stroke survivors find the show. And if you’ve had an experience you’re willing to share respectfully, positive, negative or mixed, add a comment. Those real-world perspectives help community feel less alone. And if you’d like to support the podcast and keep it going, my book is at recoveryafterstroke.com/book. And you can join the Patreon at patreon.com/recoveryafterstroke. Thanks for being here with me. And remember you’re not alone in this recovery journey. Importantly, we present many podcasts designed to give you an insight and understanding into the experiences of other individuals. Opinions and treatment protocols discussed during any podcast are the individual’s own experience, and we do not necessarily share the same opinion, nor do we recommend any treatment protocol discussed. All content on this website and any linked blog, podcast or video material controlled this website or content is created and produced for informational purposes only and is largely based on the personal experience of Bill Gassiamus. Content is intended to complement your medical treatment and support healing. It is not intended to be a substitute for professional medical advice and should not be relied on as health advice. The information is general and may not be suitable for your personal injuries, circumstances or health objectives. Do not use our content as a standalone resource to diagnose, treat, cure or prevent any disease for therapeutic purposes or as a substitute for the advice of a health professional. Never delay seeking advice or disregard the advice of a medical professional, your doctor or your rehabilitator. program based on our content. you have any questions or concerns about your health or medical condition, please seek guidance from a doctor or other medical professional. If you are experiencing a health emergency or think you might be, call 000 if in Australia or your local emergency number immediately for emergency assistance or go to the nearest hospital emergency department. Medical information changes constantly. While we aim to provide current quality information in our content, we do not provide any guarantees and assume no legal liability or responsibility for the accuracy, currency or completeness of the content. If you choose to rely on any information within our content, you do so solely at your own risk. We are careful with links we provide. However, third-party links from our website are followed at your own risk and we are not responsible for any information you find there. The post PESTO Trial Results (Etanercept After Stroke) | Interview with Professor Vincent Thijs appeared first on Recovery After Stroke.

“A Community Conversation: On the Intimacy of Urban Violence” of 2025 in New Haven, CT. When: Thursday, December 18th, 2025 6–8 p.m. Where: New Haven People's Center Address: 37 Howe Street, New Haven, CT

Rising power bills are causing increasing anxiety across Virginia, although opinions are divided about the reason for the increase and potential solutions.  Michael Pope tells us about one approach that is expected to be considered Tuesday in Congress.

At nearly 7 square miles, Griffith Park is an urban wilderness in the heart of Los Angeles. The land was a gift from Col. Griffith J. Griffith. That was very generous. He was less generous to his wife Tina seven years later when he… Well, you'll see.

Can We Agree on What Skilled Mindfulness-Based Teaching Looks Like? Lessons from Studying the MBI:TACIn this episode, Dr. Jud Brewer and Dr. Rebecca Crane explore the Mindfulness-Based Interventions: Teaching Assessment Criteria (MBI:TAC), a widely used tool for assessing the competence of mindfulness-based program (MBP) teachers. As mindfulness-based interventions (MBIs) gain popularity in clinical and workplace settings, ensuring teaching integrity and program fidelity becomes increasingly important. This study tested a training model to help mindfulness teachers reliably assess MBP teaching quality. The findings show that international MBP teachers can align their understanding of teaching competence, paving the way for standardized mindfulness education. Tune in to learn how mindfulness training is evolving to maintain high standards in research and practice.Full Reference:Crane, R. S., Hecht, F. M., Brewer, J. A., Griffith, G. M., Hartogensis, W., Koerbel, L., Moran, P., Sansom, S., Yiangou, A., & Kuyken, W. (2020). Can we agree on what skilled mindfulness-based teaching looks like? Lessons from studying the MBI:TAC. Global Advances in Health and Medicine, 0(1), 1–11. https://doi.org/10.1177/2164956120964733Let's connect on Instagram

On today's program: Casey Harper, Managing Editor for Broadcast at The Washington Stand and Host of the "Outstanding" podcast, reports on the recent developments in the Indiana state legislature's attempt at redistricting, the Trump administration's

In this thought-provoking edition of Rob McConnell Interviews, Rob welcomes Brian Griffith, historian and author of Correcting Jesus, a bold and scholarly exploration of how cultural forces, political agendas, and early church editors may have reshaped the message of Jesus over time. Griffith examines the contrast between the historical figure and the later doctrinal constructions built around him, inviting listeners to consider how teachings on compassion, justice, and human dignity evolved—and in some cases, diverged—from their original context. Through a balanced and meticulously researched discussion, he challenges long-held assumptions while encouraging open-minded inquiry into the roots of Christianity. This compelling conversation offers fresh insight into faith, history, and the enduring power of interpretation.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-x-zone-radio-tv-show--1078348/support.Please note that all XZBN radio and/or television shows are Copyright © REL-MAR McConnell Meda Company, Niagara, Ontario, Canada – www.rel-mar.com. For more Episodes of this show and all shows produced, broadcasted and syndicated from REL-MAR McConell Media Company and The 'X' Zone Broadcast Network and the 'X' Zone TV Channell, visit www.xzbn.net. For programming, distribution, and syndication inquiries, email programming@xzbn.net.We are proud to announce the we have launched TWATNews.com, launched in August 2025.TWATNews.com is an independent online news platform dedicated to uncovering the truth about Donald Trump and his ongoing influence in politics, business, and society. Unlike mainstream outlets that often sanitize, soften, or ignore stories that challenge Trump and his allies, TWATNews digs deeper to deliver hard-hitting articles, investigative features, and sharp commentary that mainstream media won't touch.These are stories and articles that you will not read anywhere else.Our mission is simple: to expose corruption, lies, and authoritarian tendencies while giving voice to the perspectives and evidence that are often marginalized or buried by corporate-controlled media

In this episode of the Tax Smart REI Podcast, Thomas Castelli and Nathan Sosa sit down with cost segregation expert Edward Griffith to break down what investors really need to know about cost segs—why engineering-driven, in-person studies deliver superior results, and how relying on cheap or software-only reports can quietly cost investors tens of thousands and increase audit risk. You'll learn: - What a cost segregation study actually is, why it matters, and which properties generate the biggest ROI - Why in-person, engineering-driven cost segregation consistently produces higher ROI and stronger IRS defensibility than software-only reports - How the timing of a study (including pre- and post-renovation) affects your tax strategy and bonus depreciation opportunities - What the full cost seg process looks like from start to finish, and how to ensure deductions actually show up on your tax return To become a client, request a consultation from Hall CPA, PLLC at go.therealestatecpa.com/3KSEev6 Subscribe to REI Daily & Enter to Win a FREE Strategy Call: go.therealestatecpa.com/41JuQBX Get the Year-End Tax Checklist: go.therealestatecpa.com/4pj63id The Tax Smart Real Estate Investors podcast is for general information purposes only and is not intended to provide, and should not be relied on for, tax, legal, or accounting advice. Information on the podcast may not constitute the most up-to-date legal or other information. No reader, user, or listener of this podcast should act or refrain from acting on the basis of information on this podcast without first seeking legal and tax advice from counsel in the relevant jurisdiction. Only your individual attorney and tax advisor can provide assurances that the information contained herein – and your interpretation of it – is applicable or appropriate to your particular situation. Use of, and access to, this podcast or any of the links or resources contained or mentioned within the podcast show and show notes do not create a relationship between the reader, user, or listener and podcast hosts, contributors, or guests. Any mention of third-party vendors, products, or services does not constitute an endorsement or recommendation. You should conduct your own due diligence before engaging with any vendor.

WEIRD: The HIDING MAN of Griffith Park and other LegendsBecome a supporter of this podcast: https://www.spreaker.com/podcast/missing-persons-mysteries--5624803/support.

As every filmmaker from D.W. Griffith to Jean-Luc Godard would tell you, no theme provides more fuel for a movie than crime does. On this week's show, Dan Webster, Nathan Weinbender, and Mary Pat Treuthart discuss two movies that focus on characters who don't so much flirt with crime but embrace it wholeheartedly.

In this episode of The Edge of Risk by IRMI, host Joel Appelbaum speaks with Austin Griffith, senior vice president at Risk Management Advisors, for an in-depth discussion on captive insurance domicile selection. Mr. Griffith outlines the core considerations that shape domicile strategy, including where risks are located, the types of policies being written, premium tax implications, regulatory environments, and the logistical realities of board meetings and travel. He also emphasizes the operational importance of domicile service levels, especially when captives need timely responses to dividend requests or coverage changes. Mr. Griffith further examines the growing trend toward home state domiciling, explaining when it can be advantageous and when limitations in state legislation or regulatory infrastructure may require organizations to look elsewhere. The episode also addresses federal and state tax considerations, procurement tax, misconceptions about "right or wrong" domiciles, and the role advisers play when working across numerous jurisdictions. Mr. Griffith closes by looking ahead at an increasingly competitive landscape as more states build out captive insurance legislation and regulatory capacity.

Dr. Ryan Griffith is the founding Dean of the Classical Christian Honors College at the University of Northwestern.  Ryan's heart for the classics was born out of his childhood and he shares his passion with us today.  

Springville-Griffith Schools Superintendent James Bialasik on the bus fire Friday morning in East Concord full 147 Fri, 05 Dec 2025 18:30:00 +0000 QK4Eti71Rds3LPwzwAPMcdQslEeMgiWd news,wben,fire,springville WBEN Extras news,wben,fire,springville Springville-Griffith Schools Superintendent James Bialasik on the bus fire Friday morning in East Concord Archive of various reports and news events 2024 © 2021 Audacy, Inc. News False

Legendary film critic Armond White joins the continuing story of The Perfume Nationalist for a wide-ranging conversation about the tragic state of cinema in 2025, modern film criticism as fake news, the greatness of Robert Altman and D.W. Griffith, and memories of Jade East and English Leather. 12/2/25 S7E85 To hear this episode and the complete continuing story of The Perfume Nationalist please subscribe on Patreon.

Danger, Dogs & Desert Secrets: Inside Bone Hash with Skye Griffith What happens when an archaeological dig uncovers something far darker than artifacts? This week, Skye Griffith takes us inside her suspenseful debut Bone Hash, where a “bone hash” suggesting prehistoric cannibalism leads archaeologist Aideen Connor into a maze of threats, violence, and long-hidden secrets. We explore the book's haunting discoveries, vivid setting, and the real-life inspiration behind its buried secrets—and of course the wonderful four-legged character, Dakota. For more information on Skye, visit: skyegriffith.com For more about my K-9 books, visit: kathleendonnelly.com Sit. Stay. Read. is a proud part of the Authors on the Air Global Network.

Sweating it Out: The Shocking Conditioning Secrets of 1923 FootballWe often think of football conditioning as a precise science of hydration, nutrition, and tailored strength programs. But a century ago, the rules of getting in shape were dramatically different. Darin Hayes of Pigskin Dispatch recently dove into the past with Timothy Brown of Football Archaeology to explore an article from the 1923 season, revealing the bizarre, and sometimes dangerous, training philosophies that shaped early gridiron stars.The episode stems from one of Tim's Tidbits titled: How Conditioning took place in 1923.The primary source for this peek into the past is the Wilson Athletic Library, a series of publications giving professional advice for the era. The specific guidance on "conditioning" came from two knowledgeable figures: Potsy Clark, a coach at Kansas (and a future NFL head coach), and John Griffith, the influential commissioner of the Big Ten. Their shared philosophy was heavily rooted in tradition and what they believed to be common sense, even when it defied basic human physiology.The Dangerous Doctrine of "Water Discipline"The most striking, and arguably most harmful, advice given was the strict adherence to water discipline: explicitly telling athletes not to drink water close to or during practice. This widespread but dangerous belief held that withholding water would make players tougher, similar to the old notion of not swimming after eating.As Timothy Brown points out, this practice put players in significant danger, especially when combined with the gear of the era. Everything worn was cotton, wool, or leather—heavy, non-wicking fabrics that made it impossible for players to perspire properly and cool down. Depriving yourself of water while wearing gear that traps heat only compounded the risk of heat-related illness.The Summer Slump PhilosophyThe coaches of 1923 also held a remarkably casual attitude toward summer training. Conditioning, in their minds, wasn't something players needed a formal program for. Instead, the ideal preparation was for athletes to be "farm boys" or to engage in "good outdoor labor" like construction, dock work, or lifeguarding. Any kind of heavy, physical work outside was deemed superior to formalized pre-season training, because that, as Brown notes, is what "training camp was for."Training camp itself was the six-week period designed to get the players in shape. This philosophy was exemplified by the tales of players like Red Grange, who gained legendary strength hauling massive blocks of ice, earning him the nickname "Wheat and Iceman."The Art of Avoiding "Staleness"Clark and Griffith's advice also focused on the non-physical elements of team administration, especially avoiding the dreaded state of "staleness." They believed a coach must walk a delicate balance: working the athletes hard, but not overworking them. If a player was "stale," it was considered the worst thing that could happen to their performance.The key barometer for a coach to know if they had pushed the team too far? Player complaints. While lazy players would complain regardless, a coach knew they had crossed the line when even the hard-working, dedicated athletes started voicing their displeasure.The contrast between the rudimentary, sometimes dangerous, conditioning of 1923 and the hyper-scientific training of today is a fascinating look at how far the gridiron has evolved. It proves that even a century ago, coaches were desperate to find that competitive edge, even if they were wrong about the most fundamental elements of human survival.Join us at the

Today, Campus Outreach International Women's Development Director, Sam Roberts, is joined by Westside member, Liz Griffith.Liz shares her longing for reconciliation and the hope of being reunited with family, even as she builds meaningful community pre-Heaven. She invites us into how God is shaping her in the waiting.This Westside Stories Advent series is designed to help you walk through the season with intentionality. As you hear how God is inviting our community into waiting, patience, and long-suffering, our prayer is that you are reminded you are not alone.

This week on The Home Builder Digital Marketing Podcast, April Griffith of GriffithX joins Greg and Kevin to discuss how home builders can move beyond basic ads and implement paid search strategies that will connect with prospective buyers and drive more qualified traffic to their websites. https://www.buildermarketingpodcast.com/episodes/296-paid-search-strategies-for-home-builders-april-griffith

When you have a child with a disability or other medical complexity, the holidays can feel like a minefield, as trauma triggers, anxiety, and grief for what we wish the holidays could have been for our families lurk around every corner.And on top of that, having to manage schedules, special diets, gift expectations, and uncomfortable commentary from friends and family can be emotionally and physically draining. The season often leaves parents of disabled children feeling left out, over-worked –and occasionally– like the celebrations might just be more trouble than they're worth.In today's episode, Amanda Griffith-Atkins and I discuss listener feedback and contributions about how complicated the holiday season feels for parents of disabled children, suggestions for how to make the holiday season feel just a little bit more manageable, and how adjusting our expectations has made a big difference for each of our families.And a big thanks to our sponsor for this episode, the makers of the incredible documentary, The Zebra & The Bear!Links:Watch The Zebra & The Bear (coming to streaming platforms the day after Thanksgiving!)Join Sticker Club! Support The Rare Life and get a thank you sticker (or four!)Follow Amanda on Instagram.Follow me on Instagram.Follow the Facebook page.Join the Facebook group Parents of Children with Rare Conditions.And if you love this podcast, please leave us a rating or review in your favorite podcast app!

10 years ago the Lord delivered me from a 5 year addiction to pornography, and by God's grace, He has sustained me in this freedom for an entire decade. Listen in as I share this wonderful testimony in detail. 

"The Venus flytrap, a devouring organism, aptly named for the goddess of love." ― Tennessee Williams, Suddenly Last Summer "The first screenplay Griffith wrote was Cardula, a Dracula-themed story involving a vampire music critic. After Corman rejected the idea, Griffith says he wrote a screenplay titled Gluttony, in which the protagonist was "a salad chef in a restaurant who would wind up cooking customers and stuff like that, you know? We couldn't do that though because of the code at the time. So I said, 'How about a man-eating plant?', and Roger said, 'Okay.' By that time, we were both drunk." - wikipedia

The story starts with two very different paths to faith—one raised in church but resistant to ministry, the other the first Christian in her family who woke up changed at seventeen. Those paths converged years later, when we compared dreams on a first date and said the quiet part out loud: we felt called to plant and pastor a church. The only mystery left was where. The answer became Chicago—its food, architecture, and energy, yes, but also its honest mix of beauty and brokenness. For Sarah, returning to her hometown felt impossible until a moment looking down from a departing plane turned resistance into a clear invitation: come back for redemption.They moved in 2019 with a solid plan—team, timeline, funding—and watched it collapse within months as the pandemic swept through the city. Our people left. Support paused. The playbook evaporated. What remained was presence: loving literal neighbors, sharing backyard meals, praying simple prayers, and letting a table culture do the work a stage couldn't. That season changed our approach and our hearts. We traded a metrics-first mindset for formation-first habits, asking what God wanted to build in us before anything He might build through us. Humility, integrity, and self-awareness became non-negotiables, and a small daily prayer—“God, give me one connection”—kept us moving with faith instead of frenzy.Send us a textWe want to help you find your next steps in ministry.Connect here with EXCEL. Ministry Partner: Christian Community Credit Union

Hosts Fran Chismar and Tom Knezick share two of their favorite episodes of The Native Plants Healthy Planet Podcast that highlight Native Plant Influencers. First is Andrew Conboy (Andrew The Arborist) to discuss native plants and social media. Topics include Andrew's path to becoming an arborist, inspirations along the way, blowing up on social media, Andrew's nonprofit Colonial Canopy Trees, and tips for the budding influencer. Up second is Griff Griffith of Redwoods Rising and the Jumpstart Nature Podcast to talk about spreading the good word on native plants.  Topics include Griff's journey into ecology, different ways to start conversations about native plants, the history and importance of the Redwood forest, equity in nature, and the story about Griff's first viral video. Intro music by Egocentric Plastic Men, outro music by Dave Bennett. Follow Andrew Conboy - Instagram / TikTok / YouTube Follow Colonial Canopy Trees - Website / Facebook / Instagram Follow Griff Griffith - Website / Facebook / TikTok / YouTube Follow Redwoods Rising - Website / Facebook / TikTok Follow Jumpstart Nature - Website Learn which Indigenous tribes lived where Here. Have a question or a comment?  Call (215) 346-6189. Follow Native Plants Healthy Planet – Website / Instagram / Facebook / YouTube Follow Fran Chismar Here. Buy a T-shirt, spread the message, and do some good. Visit Old store Here. Visit New store Here! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

It's impossible to talk about the American League's early years without talking about Clark Griffith, the former pitcher and manager who, this week 106 years ago, finally completed his quest to become a big league owner. Griffith's Senators would eventually become a laughingstock, and his legacy complicated by his complicity in perpetuating the color line, but his early years were filled with success. Mike and Bill look back on one of the longest baseball lives, a 75 year span in which Griffith was an integral part of the game, for better and for worse. Plus, happy birthday to Pat Hentgen and Jack Crooks! And farewell to Félix Torres and Bill Hepler. 

Vickie Griffith explains why mentorship isn't enough and how coaching drives real growth.

On this episode of The Running Around Charlotte Podcast, we're talking with Robert Griffith, who'll be taking on the 2025 Novant Health Charlotte half marathon. It's a journey that started last fall, when he read a quote that was quite literally life-changing. To say that he's transformed himself is to put it lightly. Whether you're running or not, we believe you'll be inspired by his story, too!

11-11-2025: Wake Up Missouri with Stephanie Bell, Peter Thiele, John Marsh, and Producer Drake

Apostolic Fellowship Church of Christ Jesus Friday Evening Service - 11/7/2025 1153 Blue Hills Ave, Bloomfield, CT 06002 We can be reached by contacting us at AFCMedia@AFC-ct.com or calling us at (860) 242-3518

This episode we trade Guts for Ganishka, focusing on a major battle between Griffith's demon knights (led by the ridiculously stupidly designed Locus in his apostle mode), which ultimately is a diversion for a certain demi-god to kidnap a certain princess. In the process however, we learn more about Ganishka and his own inhumanity and level of power. Like Guts' dong likely is...IT'S BIG.

Your child's diagnosis can reshape everything, marriages included. The same partnership that once felt effortless can become consumed by care plans, schedules, and unspoken grief. Over time, love turns into teamwork—and sometimes, survival.  In this conversation with Amanda Griffith-Atkins, we unpack the real challenges couples face when parenting through medical complexity: the imbalance of the mental load, the grief that seeps into communication, and the long road back to connection. Amanda offers practical, compassionate guidance for finding your way back to each other, even if right now, your marriage feels like it's in survival mode.If you've ever wondered what “making it work” really looks like when life is this hard, this conversation offers validation, compassion, and a path back to understanding.Links:Get a copy of How to Handle More Than You Can Handle by Amanda Griffith-Atkins.Listen to Ep 156: Should I Get a Divorce?Listen to Ep 180: Does It Get Easier?Listen to Ep 159: Sharing the Mental Load.Listen to Ep 147: Sexual Intimacy.Listen to Ep 146: The Dad Episode.Listen to Ep 182: Hobbies.Get a copy of Fair Play by Eve Rodsky.Join The Rare Life newsletter and never miss an update!Fill out our contact form to join upcoming discussion groups!Follow Amanda on Instagram @amanda.griffith.atkins!Follow us on Instagram @the_rare_life!Donate to the podcast or Contact me about sponsoring an episode.Follow the Facebook page.Join the Facebook group Parents of Children with Rare Conditions.And if you love this podcast, please leave us a rating or review in your favorite podcast app!

Join us, as we take a closer look at the death of Cathy Griffith – a 39-year-old teacher and mother, stabbed to death by her own teenage son. How to support: For extra perks including exclusive content, early release, and ad-free episodes - Go to - Patreon How to connect: Website Instagram Facebook Twitter Please check out our sponsors and help support the podcast: Nutrafol - Start your hair growth journey with Nutrafol. For a limited time, Nutrafol is offering our listeners ten dollars off your first month's subscription and free shipping when you go to Nutrafol.com and enter the promo code MADNESS Live It Up - Live It Up is offering you 15% off your first order, including subscriptions, with code MADNESS. Plus shipping's always free. Head to Letsliveitup.com/MADNESS and use code MADNESS DailyLook - Head to DailyLook.com to take your style quiz and use code MADNESS for 50% off your first order Smalls - For a limited time only, get 60% off your first order PLUS free shipping when you head to Smalls.com/MADNESS Shopify - Sign up for a one-dollar-per-month trial period at shopify.com/madness Quince - Upgrade your wardrobe with pieces made to last with Quince. Go to Quince.com/madness for free shipping on your order and 365-day returns. Greenlight - Don't wait to teach your kids real-world money skills; start your risk-free Greenlight trial today at Greenlight.com/MADNESS CBDistillery - Right now you can save 25% off your entire purchase by going to CBDistillery.com and use promo code MADNESS Research & Writing: Ryan Deininger Editing: Aiden Wolf Sources: Killer Son Murder Trial — FL v. Collin Griffith — Day 1 Killer Son Murder Trial — FL v. Collin Griffith — Day 2 Killer Son Murder Trial — FL v. Collin Griffith — Day 3 Killer Son Murder Trial — FL v. Collin Griffith — Day 4 Killer Son Murder Trial — FL v. Collin Griffith — Day 5 Killer Son Murder Trial — FL v. Collin Griffith — Day 6 Polk County Sheriff's Office Teen Accused and Absolved of Fatally Shooting Dad in 2023 Attorneys file motions in case of 17-year-old accused of murdering his mother Affidavit released in fatal shooting Oklahoma Affidavit Charles Robert Griffith Obituary Smirking Florida teen reacts as he gets away with killing both of his parents just two years apart ‘Psychopath' Son Told Deputies He'd Kill Mother a Year Before Murder ‘Psychopath' Florida Teen Accused of Killing Father in 2023 Teen Said 'I'm Not a Psychopath.' Months Later, Police Say He Stabbed His Mother to Death Teen acquitted in mom's killing -- 2 years after he was accused of shooting dad Florida Teen Accused of Stabbing Mom to Death Year After Shooting Dad Will Be Tried as Adult Florida Teen Murdered Mom by Stabbing Her in Neck 17-year-old stabs mother to death in Florida one year after killing father Florida murder case could reopen Lincoln County self-defense shooting case The shocking family secrets of Collin Griffith 'I want foster care:' Court TV Trial Recap